The cloning of a complementary DNA encoding a human TFIID TAF, $T1$, that has no known homolog in Drosophila $T2$ is now described.
TAFII55
TFIID
0
TAFII55 is shown to interact with the largest subunit ($T1$) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, $T2$, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TAFII230
CTF
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants $T1$$T2$ in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
Fas
Fas
0
In resting human epithelial and fibroblastic cells, $T1$ is phosphorylated on serine and threonine at five sites, three of which are phosphorylated in vitro by glycogen synthase kinase 3 ($T2$).
c-Jun
GSK-3
1
Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S. $T1$ displayed the same pattern of combinatorial interactions with $T2$ family proteins as Bcl-2.
Bcl-X-L
Bcl-2
0
Expressed in a murine myeloma, $T1$ was identified as a ligand for CD40 by binding to a soluble $T2$ construct.
TRAP
CD40
1
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein $T1$ and the pocket proteins pRb, p107 and pRb2/$T2$.
MyoD
p130
0
The six most frequently observed $T1$ mutations disrupt $T2$ binding in vitro.
p53
53BP2
1
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the $T1$$T2$-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
E2F4
Estrogen Receptor
0
TAFII55 is shown to interact with the largest subunit (TAFII230) of human $T1$ through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral $T2$, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TFIID
E1A
0
The $T1$-interacting region of $T2$ was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila TAFII110.
TAFII55
Sp1
1
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, $T1$, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants $T2$-LPR and Fas-FD8.
FADD
Fas
0
Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the $T1$$T2$ in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.
interleukin-1 beta
FADD
0
Residues in human leukemia inhibitory factor ($T1$) crucial for binding to both the human LIF receptor (R) and $T2$ were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.
hLIF
gp130
1
We further showed that $T1$ was comodulated on the T cell surface with $T2$, a known membrane-linked protein tyrosine phosphatase and that anti-CD26 was capable of precipitating CD45 from T cell lysates.
CD26
CD45
0
TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including $T1$, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 $T2$ proteins--through a distinct amino-terminal domain.
Sp1
Tat
0
Bcl-2 also interacted with Bcl-X-L and $T1$ and with the dominant inhibitors Bax and $T2$.
Mcl-1
Bcl-X-S
0
Thus, during myogenic differentiation, formation of $T1$ and pRb2/$T2$ containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis.
E2F4
p130
1
Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the $T1$ receptor ($T2$) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
IGF-1
IGF-1R
0
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts ($T1$$T2$ complex of proliferating myoblasts (E2F-G1/S complex).
E2F
E2F
0
Interaction of the p85 subunit of $T1$ with the insulin receptor (IR) and the $T2$ (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
PI 3-kinase
IGF-1 receptor
1
Interaction of p85 subunit of PI 3-kinase with insulin and $T1$$T2$ with insulin and IGF-1 receptors analysed by using the two-hybrid system.
IGF-1
PI 3-kinase
0
Using the cytoplasmic domain of $T1$ in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-$T2$.
Fas
FD8
0
Activation of lacZ upon interaction of p85 with IR beta(delta C-43) was 4-fold less as compared to $T1$$T2$) was 4-fold less as compared to IR beta.
IR beta
delta C-43
0
The results of his3 activation indicated that $T1$, N + C-SH2 and C-SH2 interact with both IR beta and $T2$, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
p85
IGF-1R beta
1
TAFII55 is shown to interact with the largest subunit ($T1$) of human $T2$ through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TAFII230
TFIID
0
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/$T1$$T2$ and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
cdk2
E2F4
0
Interaction of p85 and N+C-SH2 with IR beta ($T1$$T2$ and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
delta C-43
p85
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the $T1$ (bHLH) protein MyoD and the pocket proteins pRb, p107 and $T2$/p130.
myogenic basic helix-loop-helix
pRb2
0
An E2F complex containing mainly E2F4 and $T1$/$T2$ (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
pRb2
p130
0
Residues in human leukemia inhibitory factor ($T1$) crucial for binding to both the human $T2$ (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.
hLIF
LIF receptor
1
$T1$ binds exclusively to the underphosphorylated form of Rb and fails to bind to $T2$ mutants derived from patients with retinoblastoma.
Elf-1
Rb
0
Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and $T1$$T2$ family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.
Bax
Bcl-2
0
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both $T1$ and $T2$ beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IR beta
IGF-1R
0
This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta ($T1$$T2$ beta (delta C-43).
delta C-4
IGF-1R
0
Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ($T1$) for IL-4 signaling, it could not replace the function of $T2$ in allowing enhanced IL-2 binding activity.
gammac
gammac
0
This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta ($T1$$T2$ and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).
delta C-4
p85
0
Thus, $T1$ encodes a human FGF receptor with high affinity for both aFGF and $T2$.
phFGFR
bFGF
1
MyoD prevents cyclinA/cdk2 containing $T1$$T2$/cdk2 containing E2F complexes formation in terminally differentiated myocytes.
E2F
cyclinA
0
Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the $T1$$T2$ in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.
interleukin-1 beta-converting enzyme
FADD
0
The region of $T1$ most important for binding to the $T2$ is composed of residues from the amino terminus of the D-helix, carboxyl terminus of the B-helix, and C-D loop.
hLIF
hLIF-R
1
An E2F complex containing mainly E2F4 and pRb2/$T1$ ($T2$-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
p130
E2F
0
Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing $T1$$T2$ amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.
Bcl-2
Bcl-2
0
$T1$ contains a death domain homologous to the death domains of Fas and $T2$.
FADD
TNFR-1
0
$T1$ is shown to interact with the largest subunit ($T2$) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TAFII55
TAFII230
1
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, $T1$$T2$, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
hyaluronidase
elastin
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds $T1$ and Fas-FD5, a mutant of $T2$ possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
Fas
Fas
0
Thus, the C-terminal domain in $T1$ appears to exert a negative control on binding of p85 thereby providing a possible regulatory mechanism for direct activation of the $T2$ pathway.
IGF-1R
PI 3-kinase
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, $T1$, and $T2$) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
fibromodulin
decorin
0
In the present report, we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 (1F7) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased $T1$$T2$ (1F7) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity.
CD4
CD26
0
Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and $T1$$T2$, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.
Bax
Bcl-X-L
0
This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for $T1$$T2$ and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).
IGF-1R
p85
0
These findings strongly suggest that $T1$ may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of $T2$ with CD45 results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.
CD26
CD26
0
Interaction of $T1$ subunit of PI 3-kinase with $T2$ and IGF-1 receptors analysed by using the two-hybrid system.
p85
insulin
0
This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing $T1$$T2$, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).
Bcl-X-S
Bcl-X-L
0
Bcl-2 also interacted with $T1$ and Mcl-1 and with the dominant inhibitors Bax and $T2$.
Bcl-X-L
Bcl-X-S
0
From Scatchard analyses, the Kd:s for binding of $T1$ and bFGF to $T2$ were estimated to 25 pM and 41 pM, respectively.
aFGF
hFGFR-1
1
Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including $T1$, $T2$, Mcl-1, and Bax, were explored with a yeast two-hybrid system.
Bcl-X-L
Bcl-X-S
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-$T1$$T2$-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
MyoD
Estrogen Receptor
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of $T1$ possessing enhanced killing activity, but not the functionally inactive mutants Fas-$T2$ and Fas-FD8.
Fas
LPR
0
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and $T1$$T2$ beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IGF-1R beta
IR
0
Bcl-2 also interacted with $T1$ and $T2$ and with the dominant inhibitors Bax and Bcl-X-S. Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.
Bcl-X-L
Mcl-1
0
Interaction of the p85 subunit of $T1$ with the insulin receptor (IR) and the IGF-1 receptor ($T2$) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
PI 3-kinase
IGF-1R
1
Interaction of p85 subunit of PI 3-kinase with insulin and $T1$$T2$ and IGF-1 receptors analysed by using the two-hybrid system.
IGF-1
insulin
0
Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the $T1$$T2$ (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
IGF-1
IGF-1 receptor
0
Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta($T1$$T2$ (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
delta C-43
IR beta
0
Interaction of the p85 subunit of $T1$$T2$ subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
PI 3-kinase
p85
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, $T1$$T2$, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
cd44
elastin
0
Use of deletion mutants of $T1$ suggested that $T2$ homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.
Bcl-2
Bcl-2
0
TAFII55 is shown to interact with the largest subunit (TAFII230) of human $T1$$T2$ is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TFIID
TAFII55
0
In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor $T1$$T2$ DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.
MyoD
MyoD
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the $T1$$T2$ (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
E2F4
MyoD
0
Interactions of the $T1$ protein with itself and other members of the Bcl-2 family, including Bcl-X-L, $T2$, Mcl-1, and Bax, were explored with a yeast two-hybrid system.
Bcl-2
Bcl-X-S
1
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/$T1$$T2$ and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bax
Bax
0
Interaction of $T1$ and N+C-SH2 with IR beta (delta C-43) or $T2$(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
p85
IGF-1R beta
1
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix ($T1$) protein MyoD and the pocket proteins pRb, p107 and $T2$/p130.
bHLH
pRb2
0
Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing $T1$$T2$ protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.
Bcl-2
Bcl-2
0
Phosphorylation of recombinant human $T1$ proteins in vitro by $T2$ decreases their DNA-binding activity.
c-Jun
GSK-3
1
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for $T1$$T2$ heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-2
Bax
0
Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like $T1$$T2$ are similar, and like gammac, IL-13Ralpha is located on chromosome X.
gammac
gammac
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/$T1$$T2$ heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-2
Bax
0
This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, $T1$, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of $T2$ that lacks a well-conserved 63-amino acid region).
Bcl-X-L
Bcl-X
0
This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta ($T1$$T2$ and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).
delta C-4
IR beta
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, $T1$$T2$, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
cd44
hyaluronic acid synthase 2
0
Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta($T1$$T2$ and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
delta C-43
p85
0
The results of his3 activation indicated that $T1$, N + C-SH2 and C-SH2 interact with both IR beta and $T2$ beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
p85
IGF-1R
0
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with $T1$$T2$ beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IR
IGF-1R
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the $T1$$T2$) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
E2F4
MyoD
0
A cDNA encoding part of the $T1$ protein sequence interacted with the $T2$ basic-helix-loop-helix only when fused to a beta-galactosidase tag.
nucleolin
E47
1
The crystal structure of the $T1$ core domain bound to the $T2$ protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.
p53
53BP2
1
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and $T1$$T2$ and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IGF-1R beta
IR beta
0
An $T1$ complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the $T2$/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
cyclinA
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed $T1$$T2$-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
MyoD
Estrogen Receptor
0
Interaction of p85 and N+C-SH2 with IR beta ($T1$$T2$ (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
delta C-43
IR beta
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of $T1$$T2$) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
E2F
MyoD
0
$T1$ associates with the $T2$ after ligand stimulation, and binding of SHPTP2 to this receptor promotes tyrosine phosphorylation of SHPTP2.
SHPTP2
platelet-derived growth factor (PDGF) receptor
1
Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or $T1$$T2$ (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
IGF-1R
IR beta
0
TAFII55 is shown to interact with the largest subunit ($T1$) of human TFIID through its central region and with multiple activators--including Sp1, YY1, $T2$, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TAFII230
USF
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-$T1$$T2$ and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
FD5
Fas
0
Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing $T1$$T2$ amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.
Bcl-2
Bcl-2
0
Regulation of the $T1$-related transcription factor Elf-1 by binding to the $T2$ protein.
Ets
retinoblastoma
0
Interaction of the p85 subunit of PI 3-kinase with the $T1$$T2$ (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
insulin
insulin receptor
0
In the present report, we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 (1F7) led to enhanced phosphorylation of $T1$ zeta tyrosine residues and increased $T2$ associated p56lck tyrosine kinase activity.
CD3
CD4
0
Interaction of the p85 subunit of PI 3-kinase with the $T1$ ($T2$) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
insulin receptor
IR
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-$T1$) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of $T2$/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
MyoD
cyclinA
0
A second region of $T1$ that includes residues from the carboxyl terminus of the D-helix and A-B loop also had a weak influence on $T2$ binding.
hLIF
hLIF-R
1
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/$T1$$T2$ differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-2
Bcl-X-S
0
The structure of the $T1$-$T2$-heparin ternary complex provides a structural basis for the essential role of heparan sulphate in FGF signalling.
FGF1
FGFR2
1
$T1$ is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, $T2$, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TAFII55
YY1
1
Structure of the $T1$ tumor suppressor bound to the ankyrin and SH3 domains of $T2$.
p53
53BP2
1
Interactions of the $T1$ protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and $T2$, were explored with a yeast two-hybrid system.
Bcl-2
Bax
1
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/$T1$$T2$ (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
cdk2
p130
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix ($T1$$T2$ (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.
bHLH
myogenic basic helix-loop-helix
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the $T1$ (bHLH) protein MyoD and the pocket proteins pRb, $T2$ and pRb2/p130.
myogenic basic helix-loop-helix
p107
0
This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for $T1$$T2$ beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).
IGF-1R
IGF-1R
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of $T1$ possessing enhanced killing activity, but not the functionally inactive mutants $T2$-LPR and Fas-FD8.
Fas
Fas
0
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with $T1$$T2$, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IR
IGF-1R beta
0
An $T1$ complex containing mainly E2F4 and pRb2/p130 ($T2$-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
E2F
0
Activation of lacZ upon interaction of $T1$ with $T2$(delta C-43) was 4-fold less as compared to IR beta.
p85
IR beta
1
Using epitope-tagging, interaction of $T1$ basic-helix-loop-helix protein with the $T2$ protein encoded by this novel cDNA was confirmed by immunoprecipitation experiments in COS7 cells.
E47
eip1
1
TAFII55 is shown to interact with the largest subunit (TAFII230) of human $T1$ through its central region and with multiple activators--including Sp1, YY1, USF, $T2$, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TFIID
CTF
0
From Scatchard analyses, the Kd:s for binding of aFGF and $T1$ to $T2$ were estimated to 25 pM and 41 pM, respectively.
bFGF
hFGFR-1
1
TAFII55 is shown to interact with the largest subunit ($T1$) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 $T2$ proteins--through a distinct amino-terminal domain.
TAFII230
Tat
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the $T1$$T2$-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
E2F4
ER
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and $T1$-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants $T2$-LPR and Fas-FD8.
Fas
Fas
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the $T1$ containing complex following serum stimulation and this correlates with suppression of $T2$ activity and the inability of cells to re-enter the cell cycle.
E2F4
E2F
0
In this report, it is demonstrated that $T1$ contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of $T2$ both in vitro and in vivo.
Elf-1
Rb
1
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the $T1$$T2$/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
E2F4
cyclinA
0
This activation with p85 and $T1$$T2$ beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).
IGF-1R beta
IGF-1R
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of $T1$$T2$ (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
E2F
MyoD
0
Overexpression of a phosphorylation-defective form of $T1$ inhibited $T2$-dependent transcription during T cell activation.
Rb
Elf-1
0
The structure of the complex shows that the $T1$ binding site on the $T2$ core domain consists of evolutionarily conserved regions that are frequently mutated in cancer and that it overlaps the site of DNA binding.
53BP2
p53
1
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with $T1$$T2$ beta.
IR beta
IR
0
Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, $T1$$T2$, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.
Mcl-1
Bcl-X-L
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for $T1$$T2$ function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-2
Bcl-2
0
TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including $T1$, YY1, USF, $T2$, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
Sp1
CTF
0
Using a protein interaction cloning technique, we identified cDNAs that encode a novel $T1$-binding protein, termed $T2$.
Bcl-2
BAG-1
1
Whereas IL-13Ralpha serves as an alternative accessory protein to the common $T1$ (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced $T2$ binding activity.
cytokine receptor gamma chain
IL-2
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein $T1$ and the pocket proteins pRb, $T2$ and pRb2/p130.
MyoD
p107
0
Interaction of the $T1$ subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor ($T2$) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
p85
IGF-1R
0
Here we show that beta:$T1$ binds to the activin type II receptor kinase ($T2$) which induces activin binding to the type I receptor kinase SKR2 to form ActRII.beta:beta.
beta activin
ActRII
1
Interaction of the p85 subunit of $T1$ with the $T2$ receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
PI 3-kinase
insulin
0
An $T1$ complex containing mainly $T2$ and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
E2F4
0
The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of $T1$ in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of $T2$.
p53
p53
0
Thus, the C-terminal domain in IGF-1R appears to exert a negative control on binding of $T1$ thereby providing a possible regulatory mechanism for direct activation of the $T2$ pathway.
p85
PI 3-kinase
0
An E2F complex containing mainly E2F4 and $T1$/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the $T2$/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
pRb2
cyclinA
0
These results demonstrate that Rb interacts specifically with a lineage-restricted $T1$$T2$ interacts specifically with a lineage-restricted Ets transcription factor.
Ets
Rb
0
We further showed that CD26 was comodulated on the T cell surface with CD45, a known membrane-linked protein tyrosine phosphatase and that anti-CD26 was capable of precipitating $T1$$T2$, a known membrane-linked protein tyrosine phosphatase and that anti-CD26 was capable of precipitating CD45 from T cell lysates.
CD45
CD45
0
The catalytic domain of activated collagenase I ($T1$) is absolutely required for interaction with its specific inhibitor, $T2$ (TIMP-1).
MMP-1
tissue inhibitor of metalloproteinases-1
1
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-$T1$$T2$-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
MyoD
Estrogen Receptor
0
This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or $T1$$T2$, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).
Mcl-1
Bcl-X-L
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate $T1$ function, and indicate that requirements for Bcl-2/$T2$ heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-2
Bax
0
TRAP is highly similar to an identified murine CD40 ligand both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/$T1$$T2$ is highly similar to an identified murine CD40 ligand both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/lymphotoxin.
lymphotoxin
TRAP
0
After T cell activation, the phosphorylation of $T1$ results in the release of $T2$, which is correlated temporally with the activation of Elf-1-mediated transcription.
Rb
Elf-1
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, $T1$, which binds $T2$ and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
FADD
Fas
1
After T cell activation, the phosphorylation of $T1$ results in the release of Elf-1, which is correlated temporally with the activation of $T2$-mediated transcription.
Rb
Elf-1
0
265, 21561-21566) we have shown that dimerization of $T1$ was required for interaction with the cytoskeletal component $T2$.
RII alpha
microtubule-associated protein 2
1
The results of his3 activation indicated that $T1$, N + C-SH2 and C-SH2 interact with both $T2$ beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
p85
IR
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-$T1$ and $T2$-FD8.
LPR
Fas
0
MyoD prevents cyclinA/cdk2 containing $T1$$T2$ containing E2F complexes formation in terminally differentiated myocytes.
E2F
cdk2
0
This activation with $T1$ and IGF-1R beta was 4-fold less as compared to $T2$ and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).
p85
IR beta
1
$T1$ is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including $T2$, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TAFII55
Sp1
1
Withdrawal from the cell cycle of differentiating myocytes is regulated by the $T1$ (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/$T2$.
myogenic basic helix-loop-helix
p130
0
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/$T1$$T2$/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
cdk2
pRb2
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate $T1$ function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for $T2$/Bcl-2 homodimerization.
Bcl-2
Bcl-2
0
Bcl-2 also interacted with $T1$ and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S. Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as $T2$.
Bcl-X-L
Bcl-2
0
Therefore, 1) the presence of GRs and COX-2 in nasal polyps from nonallergic patients, as well as upregulation of $T1$$T2$ in nasal polyps from nonallergic patients, as well as upregulation of COX-2 expression, suggests that inflammation may play an important role in the pathophysiology of nasal polyps; and 2) glucocorticoid could be a potential treatment method for suppressing inflammatory processes.
COX-2
COX-2
0
Activation of lacZ upon interaction of p85 with IR beta($T1$$T2$ with IR beta(delta C-43) was 4-fold less as compared to IR beta.
delta C-43
p85
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, $T1$, $T2$, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
fibronectin
cd44
0
Bcl-2 also interacted with $T1$ and Mcl-1 and with the dominant inhibitors $T2$ and Bcl-X-S. Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.
Bcl-X-L
Bax
0
Regulation of the $T1$-related transcription factor $T2$ by binding to the retinoblastoma protein.
Ets
Elf-1
0
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing $T1$$T2$ containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
cdk2
0
In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector $T1$$T2$ downstream effector p21 are induced.
p21
MyoD
0
Measurement of $T1$ I3A,I5A interaction with the human thyroid AKAP, $T2$, by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold.
RII alpha
Ht 31
1
An $T1$ complex containing mainly E2F4 and $T2$/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
pRb2
0
Interaction of the p85 subunit of PI 3-kinase with the $T1$ receptor (IR) and the $T2$ receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
insulin
IGF-1
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the $T1$ (bHLH) protein MyoD and the pocket proteins $T2$, p107 and pRb2/p130.
myogenic basic helix-loop-helix
pRb
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-$T1$$T2$-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
MyoD
ER
0
Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the $T1$$T2$ suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.
Bcl-2
Bcl-2
0
TRAP is highly similar to an identified murine $T1$ both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/$T2$.
CD40 ligand
lymphotoxin
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, $T1$, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-$T2$ and Fas-FD8.
FADD
LPR
0
Using SHPTP2 as bait and supplying an exogenous tyrosine kinase gene to the yeast cells, we have found that $T1$ interacts with another signaling protein, $T2$.
SHPTP2
Grb7
1
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts ($T1$$T2$/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
pRb2
0
$T1$ is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, $T2$, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TAFII55
CTF
1
Coassociation of $T1$ (dipeptidyl peptidase IV) with $T2$ on the surface of human T lymphocytes.
CD26
CD45
1
In the present study, we examined the presence of glucocorticoid receptors (GRs) and cyclooxygenase-2 ($T1$$T2$ (COX-2) in the nasal polyps of nonallergic patients as compared with normal controls.
COX-2
cyclooxygenase-2
0
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with $T1$$T2$, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IR beta
IGF-1R beta
0
In the present report, we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 (1F7) led to enhanced phosphorylation of $T1$$T2$ (1F7) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity.
CD3
CD26
0
This activation with $T1$ and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for $T2$ (delta C-43).
p85
IGF-1R beta
1
MyoD prevents $T1$/$T2$ containing E2F complexes formation in terminally differentiated myocytes.
cyclinA
cdk2
1
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, $T1$$T2$, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
fibromodulin
collagenase
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD ($T1$-MyoD) chimerae, we found that estrogen directed $T2$ activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
ER
MyoD
0
Regulation of the Ets-related transcription factor $T1$ by binding to the $T2$ protein.
Elf-1
retinoblastoma
1
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, $T1$, which binds Fas and $T2$-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
FADD
Fas
1
This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, $T1$$T2$, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).
Bcl-X-L
Bcl-2
0
The cloning of a complementary DNA encoding a human $T1$ TAF, $T2$, that has no known homolog in Drosophila TFIID is now described.
TFIID
TAFII55
0
An E2F complex containing mainly $T1$ and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the $T2$/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F4
cyclinA
0
The present study has shown that cell surface $T1$ binds to the $T2$ mediating its mitogenic activity.
calreticulin
B beta chain of fibrinogen
1
The structure provides evidence that the $T1$-p53 complex forms in vivo and may have a critical role in the $T2$ pathway of tumor suppression.
53BP2
p53
0
Using the cytoplasmic domain of $T1$ in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and $T2$-FD8.
Fas
Fas
0
Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or $T1$$T2$ (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
IGF-1R beta
IR beta
0
Our data indicate that, in differentiating myocytes, one mechanism through which MyoD induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation-associated cdks-containing $T1$$T2$ induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation-associated cdks-containing E2F complexes formation.
E2F
MyoD
0
Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for $T1$ signaling, it could not replace the function of gammac in allowing enhanced $T2$ binding activity.
IL-4
IL-2
0
Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing $T1$$T2$ suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.
Bcl-2
Bcl-2
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, $T1$, hyaluronidase, fibronectin, cd44, $T2$, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
hyaluronic acid synthase 2
fibromodulin
0
TAFII55 is shown to interact with the largest subunit ($T1$) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral $T2$, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TAFII230
E1A
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix ($T1$) protein $T2$ and the pocket proteins pRb, p107 and pRb2/p130.
bHLH
MyoD
0
The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant $T1$ and $T2$ (a CBP-related protein).
CBP
p300
0
In contrast to LexA/Bcl-2 fusion proteins, expression of a LexA/$T1$$T2$ fusion proteins, expression of a LexA/Bax protein was lethal to yeast.
Bax
Bcl-2
0
This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for $T1$$T2$ and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).
IGF-1R beta
IR beta
0
$T1$ also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S. Bcl-X-L displayed the same pattern of combinatorial interactions with $T2$ family proteins as Bcl-2.
Bcl-2
Bcl-2
0
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with $T1$$T2$ beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IR beta
IR
0
Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by $T1$$T2$ in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.
CrmA
FADD
0
Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing $T1$$T2$ homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.
Bcl-2
Bcl-2
0
Interaction of the $T1$ subunit of PI 3-kinase with the $T2$ (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
p85
insulin receptor
0
In contrast, in normal nasal tissues, $T1$ labeling was only found in the vascular wall, and the expression was weaker--a finding demonstrating that $T2$ is upregulated in nasal polyps.
COX-2
COX-2
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/$T1$$T2$ and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-2
Bax
0
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with $T1$$T2$ beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IR beta
IGF-1R
0
FADD contains a death domain homologous to the death domains of $T1$ and $T2$.
Fas
TNFR-1
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix ($T1$) protein MyoD and the pocket proteins pRb, p107 and pRb2/$T2$.
bHLH
p130
0
Co-immunoprecipitation experiments demonstrated an association between $T1$ and $T2$ in resting normal human T cells.
Elf-1
Rb
1
TAFII55 is shown to interact with the largest subunit ($T1$) of human TFIID through its central region and with multiple activators--including Sp1, $T2$, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TAFII230
YY1
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, $T1$$T2$, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
fibronectin
hyaluronidase
0
Activation of lacZ upon interaction of $T1$ with IR beta(delta C-43) was 4-fold less as compared to $T2$.
p85
IR beta
1
$T1$ also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S. $T2$ displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.
Bcl-2
Bcl-X-L
0
This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing $T1$ (an alternatively spliced form of $T2$ that lacks a well-conserved 63-amino acid region).
Bcl-X-S
Bcl-X
0
The structure provides evidence that the 53BP2-$T1$ complex forms in vivo and may have a critical role in the $T2$ pathway of tumor suppression.
p53
p53
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein $T1$ and the pocket proteins pRb, p107 and $T2$/p130.
MyoD
pRb2
0
$T1$ contains a death domain homologous to the death domains of $T2$ and TNFR-1.
FADD
Fas
0
Peptide sequencing and Western blot analysis established that the 265-kD protein was $T1$ ($T2$),a recently identified transcriptional coactivator.
CBP
CREB-binding protein
0
$T1$ also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors $T2$ and Bcl-X-S. Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.
Bcl-2
Bax
1
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts ($T1$$T2$/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
cyclinA
0
Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing $T1$$T2$ homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.
Bcl-2
Bcl-2
0
$T1$ prevents cyclinA/$T2$ containing E2F complexes formation in terminally differentiated myocytes.
MyoD
cdk2
0
Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, $T1$$T2$, Mcl-1, and Bax, were explored with a yeast two-hybrid system.
Mcl-1
Bcl-X-S
0
Whereas IL-13Ralpha serves as an alternative accessory protein to the common $T1$ (gammac) for $T2$ signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.
cytokine receptor gamma chain
IL-4
0
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing $T1$$T2$/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
cyclinA
0
Whereas IL-13Ralpha serves as an alternative accessory protein to the common $T1$ (gammac) for IL-4 signaling, it could not replace the function of $T2$ in allowing enhanced IL-2 binding activity.
cytokine receptor gamma chain
gammac
0
Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the $T1$$T2$-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.
interleukin-1 beta
Fas
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins $T1$, p107 and $T2$/p130.
pRb
pRb2
0
Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or $T1$$T2$ beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
IGF-1R beta
IGF-1R
0
Activation of lacZ upon interaction of p85 with IR beta(delta C-43) was 4-fold less as compared to $T1$$T2$(delta C-43) was 4-fold less as compared to IR beta.
IR beta
IR beta
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for $T1$/Bax heterodimerization may be different from those for $T2$/Bcl-2 homodimerization.
Bcl-2
Bcl-2
0
This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for $T1$$T2$ was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).
IGF-1R beta
IGF-1R beta
0
$T1$ also interacted with Bcl-X-L and $T2$ and with the dominant inhibitors Bax and Bcl-X-S. Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.
Bcl-2
Mcl-1
1
Expressed in a murine myeloma, $T1$ was identified as a ligand for $T2$ by binding to a soluble CD40 construct.
TRAP
CD40
1
This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing $T1$$T2$ but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).
Bcl-X-S
Mcl-1
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-$T1$) chimerae, we found that estrogen directed $T2$ activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
MyoD
MyoD
0
An E2F complex containing mainly $T1$ and pRb2/$T2$ (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F4
p130
1
Interaction of p85 subunit of PI 3-kinase with $T1$$T2$ with insulin and IGF-1 receptors analysed by using the two-hybrid system.
insulin
PI 3-kinase
0
Interaction of the p85 subunit of PI 3-kinase with the insulin receptor ($T1$) and the $T2$ (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
IR
IGF-1 receptor
0
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing $T1$$T2$ (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
p130
0
$T1$ is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral $T2$, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TAFII55
E1A
1
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts ($T1$$T2$-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
E2F
0
Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, $T1$$T2$ family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.
Mcl-1
Bcl-2
0
We further showed that CD26 was comodulated on the T cell surface with CD45, a known membrane-linked protein tyrosine phosphatase and that anti-$T1$ was capable of precipitating $T2$ from T cell lysates.
CD26
CD45
0
Interactions of the $T1$ protein with itself and other members of the Bcl-2 family, including $T2$, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.
Bcl-2
Bcl-X-L
1
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the $T1$/$T2$ containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
cyclinA
cdk2
1
Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, $T1$$T2$ family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.
Bcl-X-S
Bcl-2
0
Interaction of the p85 subunit of PI 3-kinase with the $T1$ (IR) and the IGF-1 receptor ($T2$) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
insulin receptor
IGF-1R
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, $T1$$T2$, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
fibronectin
hyaluronic acid synthase 2
0
The crystal structure of the p53 core domain bound to the $T1$ protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of $T2$.
53BP2
p53
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for $T1$$T2$ and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-2
Bax
0
A point mutation in FADD, analogous to the lpr mutation of $T1$, abolishes its ability to bind $T2$, suggesting a death domain to death domain interaction.
Fas
Fas
0
An E2F complex containing mainly $T1$ and $T2$/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F4
pRb2
1
Use of the two hybrid system to detect the association of the protein-tyrosine-phosphatase, $T1$, with another SH2-containing protein, $T2$.
SHPTP2
Grb7
1
In the present report, we demonstrated that modulation of $T1$ from T cell surface induced by anti$T2$ (1F7) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity.
CD26
CD26
0
Comparison of messenger RNA gene expression of extracellular matrix proteins ($T1$, collagenase, $T2$, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
procollagen I
elastin
0
The structure provides evidence that the $T1$-$T2$ complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression.
53BP2
p53
1
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and $T1$$T2$, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
decorin
elastin
0
The two residues of $T1$ that contribute the majority of free energy for $T2$ binding, Phe-156 and Lys-159 are surrounded by other residues which have only a moderate impact.
hLIF
hLIF-R
1
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, $T1$$T2$, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
cd44
collagenase
0
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing $T1$$T2$ and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
E2F4
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-$T1$$T2$ (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
MyoD
MyoD
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants $T1$-LPR and $T2$-FD8.
Fas
Fas
0
Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors $T1$ and Bcl-X-S. Bcl-X-L displayed the same pattern of combinatorial interactions with $T2$ family proteins as Bcl-2.
Bax
Bcl-2
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for $T1$/$T2$ homodimerization.
Bcl-2
Bcl-2
1
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and $T1$-$T2$, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
Fas
FD5
0
Whereas $T1$ serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for $T2$ signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.
IL-13Ralpha
IL-4
1
A point mutation in $T1$, analogous to the lpr mutation of $T2$, abolishes its ability to bind Fas, suggesting a death domain to death domain interaction.
FADD
Fas
0
The internal binding site thus revealed was not altered by further mutating Y960/F for $T1$ or Y950/F for $T2$.
IR
IGF-1R
0
TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including $T1$, YY1, $T2$, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
Sp1
USF
0
Interaction of the p85 subunit of PI 3-kinase with the $T1$$T2$ subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
insulin
p85
0
Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of $T1$ in allowing enhanced $T2$ binding activity.
gammac
IL-2
0
TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including $T1$, $T2$, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
Sp1
YY1
0
$T1$ is a multisubunit protein complex comprised of the TATA-binding protein ($T2$) and multiple TBP-associated factors (TAFs).
TFIID
TBP
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, $T1$, hyaluronidase, fibronectin, cd44, fibromodulin, and $T2$) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
hyaluronic acid synthase 2
decorin
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of $T1$$T2$-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
E2F
Estrogen Receptor
0
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with $T1$$T2$, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IR beta
p85
0
Interaction of the p85 subunit of $T1$ with the $T2$ (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
PI 3-kinase
insulin receptor
1
Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing $T1$$T2$ suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.
Bcl-2
Bcl-2
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of $T1$ possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-$T2$.
Fas
FD8
0
This cytotoxicity could be abrogated by B42 fusion proteins containing $T1$, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of $T2$ that lacks a well-conserved 63-amino acid region).
Bcl-2
Bcl-X
0
These findings strongly suggest that $T1$ may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with $T2$ results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.
CD26
CD45
0
The $T1$ gene product ($T2$) is a nuclear phosphoprotein that regulates cell cycle progression.
retinoblastoma
Rb
0
Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors $T1$ and $T2$.
Bax
Bcl-X-S
0
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts ($T1$$T2$ and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
E2F4
0
A cDNA clone, designated TRAP ($T1$$T2$ (TNF-related activation protein) was isolated from a collection of T cell activation genes.
TNF-related activation protein
TRAP
0
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing $T1$$T2$/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
pRb2
0
Bcl-2 also interacted with Bcl-X-L and $T1$ and with the dominant inhibitors Bax and Bcl-X-S. Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as $T2$.
Mcl-1
Bcl-2
0
Interaction of the $T1$ subunit of PI 3-kinase with the insulin receptor (IR) and the $T2$ receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
p85
IGF-1
0
Thus, $T1$ encodes a human FGF receptor with high affinity for both $T2$ and bFGF.
phFGFR
aFGF
1
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, $T1$$T2$, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
hyaluronic acid synthase 2
collagenase
0
TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, $T1$, $T2$, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
YY1
USF
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/$T1$$T2$ (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
cdk2
MyoD
0
Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for $T1$ signaling, it could not replace the function of $T2$ in allowing enhanced IL-2 binding activity.
IL-4
gammac
0
This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or Mcl-1 but not those containing $T1$$T2$, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).
Bcl-X-S
Bcl-2
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for $T1$$T2$ differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-2
Bcl-X-S
0
Elf-1 binds exclusively to the underphosphorylated form of $T1$ and fails to bind to $T2$ mutants derived from patients with retinoblastoma.
Rb
Rb
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and $T1$$T2$ in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
Fas
Fas
0
Cloning of $T1$, a ligand for $T2$ on human T cells.
TRAP
CD40
1
SREBP transcriptional activity is mediated through an interaction with the $T1$$T2$.
CREB
CREB-binding protein
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-$T1$, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-$T2$.
FD5
FD8
0
TFIID is a multisubunit protein complex comprised of the $T1$$T2$ is a multisubunit protein complex comprised of the TATA-binding protein (TBP) and multiple TBP-associated factors (TAFs).
TATA-binding protein
TFIID
0
The crystal structure of the $T1$ core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of $T2$.
p53
p53
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, $T1$$T2$, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
hyaluronic acid synthase 2
elastin
0
Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors $T1$ and Bcl-X-S. Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as $T2$.
Bax
Bcl-2
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and $T1$/$T2$.
pRb2
p130
0
Thus, the C-terminal domain in $T1$ appears to exert a negative control on binding of $T2$ thereby providing a possible regulatory mechanism for direct activation of the PI 3-kinase pathway.
IGF-1R
p85
1
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/$T1$ to the E2F4 containing complex following serum stimulation and this correlates with suppression of $T2$ activity and the inability of cells to re-enter the cell cycle.
cdk2
E2F
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for $T1$/$T2$ heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-2
Bax
1
TAFII55 is shown to interact with the largest subunit (TAFII230) of human $T1$ through its central region and with multiple activators--including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 $T2$ proteins--through a distinct amino-terminal domain.
TFIID
Tat
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for $T1$$T2$ differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-2
Bcl-X-S
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate $T1$$T2$ and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-2
Bax
0
The core domain contains the sequence-specific DNA binding activity and the in vitro $T1$ protein binding activity of $T2$.
53BP2
p53
1
The cloning of a complementary DNA encoding a human $T1$ TAF, TAFII55, that has no known homolog in Drosophila $T2$ is now described.
TFIID
TFIID
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, $T1$$T2$, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
hyaluronidase
procollagen I
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the $T1$$T2$ activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
E2F4
MyoD
0
A point mutation in $T1$, analogous to the lpr mutation of Fas, abolishes its ability to bind $T2$, suggesting a death domain to death domain interaction.
FADD
Fas
1
Interaction of the p85 subunit of $T1$ with the insulin receptor ($T2$) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
PI 3-kinase
IR
1
This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta ($T1$$T2$ (delta C-43).
delta C-4
IGF-1R beta
0
Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ($T1$) for $T2$ signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.
gammac
IL-4
0
Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing $T1$$T2$ homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.
Bcl-2
Bcl-2
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of $T1$ possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and $T2$-FD8.
Fas
Fas
0
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both $T1$ beta and $T2$ beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IR
IGF-1R
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and $T1$$T2$, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
decorin
collagenase
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/$T1$$T2$/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-2
Bcl-2
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and $T1$$T2$, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
decorin
procollagen I
0
Abolition of the $T1$ binding site in $T2$ created antagonists of LIF action.
gp130
hLIF
1
Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, $T1$, and $T2$, were explored with a yeast two-hybrid system.
Mcl-1
Bax
0
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts ($T1$$T2$ complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
E2F
0
Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the $T1$$T2$ homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.
Bcl-2
Bcl-2
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/$T1$$T2$ function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-2
Bcl-2
0
TAFII55 is shown to interact with the largest subunit (TAFII230) of human $T1$ through its central region and with multiple activators--including $T2$, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TFIID
Sp1
0
Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the $T1$$T2$-converting enzyme.
interleukin-1 beta-converting enzyme
interleukin-1 beta
0
This activation with p85 and $T1$$T2$ and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).
IGF-1R
p85
0
Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, $T1$$T2$, IL-13Ralpha is located on chromosome X.
IL-13Ralpha
gammac
0
Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or $T1$$T2$ and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
IGF-1R
p85
0
$T1$ also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and $T2$.
Bcl-2
Bcl-X-S
1
Interaction of the p85 subunit of $T1$ with the insulin receptor (IR) and the $T2$ receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
PI 3-kinase
IGF-1
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein $T1$ and the pocket proteins $T2$, p107 and pRb2/p130.
MyoD
pRb
0
$T1$ prevents $T2$/cdk2 containing E2F complexes formation in terminally differentiated myocytes.
MyoD
cyclinA
0
Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, $T1$$T2$ and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.
IL-13Ralpha
IL-13Ralpha
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, $T1$, fibromodulin, and $T2$) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
cd44
decorin
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds $T1$$T2$ in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
Fas
Fas
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants $T1$-$T2$ and Fas-FD8.
Fas
LPR
0
Interaction of the p85 subunit of PI 3-kinase with the $T1$ (IR) and the $T2$ receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
insulin receptor
IGF-1
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds $T1$ and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants $T2$-LPR and Fas-FD8.
Fas
Fas
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, $T1$$T2$, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
fibromodulin
procollagen I
0
This activation with p85 and IGF-1R beta was 4-fold less as compared to $T1$$T2$ was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).
IR beta
IGF-1R beta
0
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts ($T1$$T2$ containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
cdk2
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, $T1$$T2$, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
fibromodulin
elastin
0
Activation of lacZ upon interaction of p85 with IR beta($T1$$T2$(delta C-43) was 4-fold less as compared to IR beta.
delta C-43
IR beta
0
Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing $T1$$T2$ suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.
Bcl-2
Bcl-2
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and $T1$-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and $T2$-FD8.
Fas
Fas
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins $T1$, $T2$ and pRb2/p130.
pRb
p107
0
Activation of $T1$ results in rapid, site-specific dephosphorylation of $T2$ at one or more of these three sites and is coincident with increased AP-1-binding activity.
protein kinase C
c-Jun
1
Comparison of messenger RNA gene expression of extracellular matrix proteins ($T1$, $T2$, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
procollagen I
collagenase
0
Interaction of the p85 subunit of PI 3-kinase with the $T1$ receptor ($T2$) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
insulin
IR
0
The carboxy-terminal region of $T1$ has previously been shown to interact directly with $T2$, a cytoplasmic component of the dystrophin-glycoprotein complex, by in vitro biochemical studies such as overlay assay or immunoprecipitation.
dystrophin
alpha1 syntrophin
1
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with $T1$$T2$ and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IR beta
IR beta
0
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/$T1$$T2$ complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
cdk2
E2F
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD ($T1$$T2$ (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
ER
MyoD
0
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing $T1$$T2$ complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
E2F
0
The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant CBP and p300 (a $T1$$T2$ and p300 (a CBP-related protein).
CBP
CBP
0
Interaction of $T1$ subunit of $T2$ with insulin and IGF-1 receptors analysed by using the two-hybrid system.
p85
PI 3-kinase
0
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing $T1$$T2$-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
E2F
0
Interaction of the $T1$ subunit of PI 3-kinase with the insulin receptor ($T2$) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
p85
IR
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the $T1$$T2$ to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
E2F4
cdk2
0
Bcl-2 also interacted with $T1$ and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S. $T2$ displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.
Bcl-X-L
Bcl-X-L
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of $T1$$T2$ activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
cyclinA
MyoD
0
In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of $T1$$T2$ binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo.
Rb
Rb
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, $T1$, $T2$, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
hyaluronic acid synthase 2
hyaluronidase
0
The results of his3 activation indicated that $T1$, N + C-SH2 and C-SH2 interact with both $T2$ and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
p85
IR beta
1
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/$T1$$T2$) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
cdk2
MyoD
0
Residues in human $T1$ (hLIF) crucial for binding to both the human LIF receptor (R) and $T2$ were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.
leukemia inhibitory factor
gp130
1
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/$T1$$T2$-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
cdk2
E2F
0
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both $T1$$T2$ and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IR
IR beta
0
An E2F complex containing mainly E2F4 and pRb2/$T1$ (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the $T2$/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
p130
cyclinA
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, $T1$$T2$, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
cd44
procollagen I
0
These findings strongly suggest that CD26 may be closely associated with the $T1$ protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of $T2$ with CD45 results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.
CD45
CD26
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins $T1$, p107 and pRb2/$T2$.
pRb
p130
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, $T1$, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-$T2$.
FADD
FD8
0
TAFII55 is shown to interact with the largest subunit (TAFII230) of human $T1$ through its central region and with multiple activators--including Sp1, YY1, $T2$, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TFIID
USF
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, $T1$$T2$, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
fibronectin
procollagen I
0
The mitogenic effects of the $T1$ are mediated through cell surface $T2$.
B beta chain of fibrinogen
calreticulin
1
Interaction of the $T1$ subunit of PI 3-kinase with the insulin receptor (IR) and the $T2$ (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
p85
IGF-1 receptor
0
Interaction of p85 subunit of PI 3-kinase with insulin and $T1$$T2$ subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system.
IGF-1
p85
0
Interaction of the p85 subunit of PI 3-kinase with the $T1$ receptor (IR) and the IGF-1 receptor ($T2$) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
insulin
IGF-1R
0
Measurement of $T1$ I3A,I5A interaction with the human $T2$, Ht 31, by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold.
RII alpha
thyroid AKAP
1
This activation with p85 and IGF-1R beta was 4-fold less as compared to $T1$$T2$ beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).
IR beta
IGF-1R
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, $T1$$T2$, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
hyaluronidase
collagenase
0
$T1$ also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S. Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as $T2$.
Bcl-2
Bcl-2
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, $T1$$T2$, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
elastin
collagenase
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-$T1$, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants $T2$-LPR and Fas-FD8.
FD5
Fas
0
Bcl-2 also interacted with Bcl-X-L and $T1$ and with the dominant inhibitors $T2$ and Bcl-X-S. Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.
Mcl-1
Bax
0
In resting human epithelial and fibroblastic cells, $T1$ is phosphorylated on serine and threonine at five sites, three of which are phosphorylated in vitro by $T2$ (GSK-3).
c-Jun
glycogen synthase kinase 3
1
Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain ($T1$) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced $T2$ binding activity.
gammac
IL-2
0
We further showed that CD26 was comodulated on the T cell surface with CD45, a known membrane-linked protein tyrosine phosphatase and that anti-CD26 was capable of precipitating $T1$$T2$ was comodulated on the T cell surface with CD45, a known membrane-linked protein tyrosine phosphatase and that anti-CD26 was capable of precipitating CD45 from T cell lysates.
CD45
CD26
0
Thus, during myogenic differentiation, formation of $T1$ and $T2$/p130 containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis.
E2F4
pRb2
1
Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S. Bcl-X-L displayed the same pattern of combinatorial interactions with $T1$ family proteins as $T2$.
Bcl-2
Bcl-2
0
Using the cytoplasmic domain of $T1$ in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-$T2$ and Fas-FD8.
Fas
LPR
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-$T1$ and Fas-$T2$.
LPR
FD8
0
Residues in human $T1$ (hLIF) crucial for binding to both the human $T2$ (R) and gp130 were identified by analysis of alanine scanning mutants of hLIF in assays for both receptor binding and bioactivity.
leukemia inhibitory factor
LIF receptor
1
Interaction of the p85 subunit of PI 3-kinase with the insulin receptor ($T1$) and the $T2$ receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
IR
IGF-1
0
An E2F complex containing mainly E2F4 and pRb2/p130 ($T1$-G0/G1 complex) appears when DNA synthesis arrests, replacing the $T2$/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
cyclinA
0
An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts ($T1$$T2$ (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
p130
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix ($T1$) protein MyoD and the pocket proteins $T2$, p107 and pRb2/p130.
bHLH
pRb
0
Cloning and functional analysis of $T1$: a novel $T2$-binding protein with anti-cell death activity.
BAG-1
Bcl-2
1
This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or $T1$ but not those containing Bcl-X-S (an alternatively spliced form of $T2$ that lacks a well-conserved 63-amino acid region).
Mcl-1
Bcl-X
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/$T1$$T2$-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
cdk2
ER
0
An $T1$ complex containing mainly E2F4 and pRb2/$T2$ (E2F-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F
p130
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, $T1$, $T2$, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
cd44
fibromodulin
0
$T1$ also interacted with $T2$ and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S. Bcl-X-L displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.
Bcl-2
Bcl-X-L
1
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, $T1$, which binds Fas and Fas-$T2$, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
FADD
FD5
1
In the present report, we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 (1F7) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased $T1$$T2$ from T cell surface induced by antiCD26 (1F7) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity.
CD4
CD26
0
TFIID is a multisubunit protein complex comprised of the $T1$ ($T2$) and multiple TBP-associated factors (TAFs).
TATA-binding protein
TBP
0
TRAP is highly similar to an identified murine $T1$$T2$ is highly similar to an identified murine CD40 ligand both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/lymphotoxin.
CD40 ligand
TRAP
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, $T1$, cd44, $T2$, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
fibronectin
fibromodulin
0
Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and $T1$$T2$ and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.
gammac
IL-13Ralpha
0
The crystal structure of the p53 core domain bound to the $T1$ protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of $T2$ in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.
53BP2
p53
0
Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing $T1$$T2$ amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.
Bcl-2
Bcl-2
0
This activation with p85 and IGF-1R beta was 4-fold less as compared to $T1$ and was somewhat increased (2-fold) for $T2$ beta (delta C-43).
IR beta
IGF-1R
0
$T1$ is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including Sp1, YY1, $T2$, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TAFII55
USF
1
Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, $T1$$T2$ are similar, and like gammac, IL-13Ralpha is located on chromosome X.
IL-13Ralpha
gammac
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for $T1$$T2$ and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-2
Bax
0
The experiments were performed with the cytoplasmic beta domain (wild type or mutated) of $T1$ and IGF-1R and $T2$ or its subdomains (N + C-SH2, N-SH2, C-SH2, SH3 + N-SH2).
IR
p85
0
In this report, it is demonstrated that $T1$ contains a sequence motif that is highly related to the $T2$ binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo.
Elf-1
Rb
0
The experiments were performed with the cytoplasmic beta domain (wild type or mutated) of IR and $T1$ and $T2$ or its subdomains (N + C-SH2, N-SH2, C-SH2, SH3 + N-SH2).
IGF-1R
p85
0
The findings suggest a model whereby Bax and $T1$$T2$ and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-X-S
Bax
0
Interaction of the p85 subunit of PI 3-kinase with the insulin receptor ($T1$) and the IGF-1 receptor ($T2$) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
IR
IGF-1R
0
Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing $T1$$T2$ protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.
Bcl-2
Bcl-2
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of $T1$$T2$-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
cyclinA
Estrogen Receptor
0
In an unbiased search for potential coactivators of SREBP, we isolated a protein of 265 kD from HeLa cells that directly bound $T1$ and $T2$.
SREBP-1
SREBP-2
0
Interaction of the p85 subunit of PI 3-kinase with the $T1$ (IR) and the $T2$ (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
insulin receptor
IGF-1 receptor
0
This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for $T1$$T2$ beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).
IGF-1R beta
IGF-1R
0
This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for $T1$$T2$ beta (delta C-43).
IGF-1R beta
IGF-1R
0
Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors $T1$ and Bcl-X-S. $T2$ displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.
Bax
Bcl-X-L
0
Only weak $T1$ binding activity was found in cells transfected with only $T2$; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.
IL-13
IL-13Ralpha
1
Bcl-2 also interacted with $T1$ and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S. Bcl-X-L displayed the same pattern of combinatorial interactions with $T2$ family proteins as Bcl-2.
Bcl-X-L
Bcl-2
0
Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or $T1$$T2$) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
IGF-1R beta
delta C-43
0
We further showed that CD26 was comodulated on the T cell surface with CD45, a known membrane-linked protein tyrosine phosphatase and that anti-$T1$$T2$, a known membrane-linked protein tyrosine phosphatase and that anti-CD26 was capable of precipitating CD45 from T cell lysates.
CD26
CD45
0
These findings strongly suggest that CD26 may be closely associated with the $T1$ protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with $T2$ results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.
CD45
CD45
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix ($T1$) protein MyoD and the pocket proteins pRb, $T2$ and pRb2/p130.
bHLH
p107
0
Residues in $T1$ from both the A- and C-helices are involved in binding the $T2$ co-receptor.
hLIF
gp130
1
Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by $T1$$T2$-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.
CrmA
Fas
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and $T1$-$T2$.
Fas
FD8
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, $T1$, cd44, fibromodulin, and $T2$) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
fibronectin
decorin
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants $T1$-LPR and Fas-$T2$.
Fas
FD8
0
This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta ($T1$$T2$ was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).
delta C-4
IGF-1R beta
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds $T1$ and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-$T2$.
Fas
FD8
0
Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta($T1$$T2$) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
delta C-43
delta C-43
0
We further showed that CD26 was comodulated on the T cell surface with CD45, a known membrane-linked protein tyrosine phosphatase and that anti-$T1$$T2$ was comodulated on the T cell surface with CD45, a known membrane-linked protein tyrosine phosphatase and that anti-CD26 was capable of precipitating CD45 from T cell lysates.
CD26
CD26
0
Thus, during myogenic differentiation, formation of E2F4 and $T1$/$T2$ containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis.
pRb2
p130
0
TAFII55 is shown to interact with the largest subunit ($T1$) of human TFIID through its central region and with multiple activators--including $T2$, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TAFII230
Sp1
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, $T1$, which binds Fas and Fas-FD5, a mutant of $T2$ possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
FADD
Fas
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of $T1$$T2$-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
E2F
ER
0
In the present report, we demonstrated that modulation of CD26 from T cell surface induced by antiCD26 (1F7) led to enhanced phosphorylation of $T1$$T2$ from T cell surface induced by antiCD26 (1F7) led to enhanced phosphorylation of CD3 zeta tyrosine residues and increased CD4 associated p56lck tyrosine kinase activity.
CD3
CD26
0
These findings suggest that FADD may play an important role in the proximal signal transduction of $T1$$T2$ may play an important role in the proximal signal transduction of Fas.
Fas
FADD
0
Expressed in a murine myeloma, TRAP was identified as a ligand for CD40 by binding to a soluble $T1$$T2$ by binding to a soluble CD40 construct.
CD40
CD40
0
We propose that $T1$ is present in resting cells in a latent, phosphorylated form that can be activated by site-specific dephosphorylation in response to $T2$ activation.
c-Jun
protein kinase C
1
In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when $T1$$T2$ complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.
MyoD
E2F
0
$T1$ binds exclusively to the underphosphorylated form of $T2$ and fails to bind to Rb mutants derived from patients with retinoblastoma.
Elf-1
Rb
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, $T1$ and pRb2/$T2$.
p107
p130
0
TAFII55 is shown to interact with the largest subunit (TAFII230) of human $T1$ through its central region and with multiple activators--including Sp1, $T2$, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
TFIID
YY1
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and $T1$-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-$T2$ and Fas-FD8.
Fas
LPR
0
Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the $T1$$T2$, a specific inhibitor of the interleukin-1 beta-converting enzyme.
interleukin-1 beta
CrmA
0
We demonstrate that $T1$ binds to $T2$ in vitro under conditions where the latter is tyrosine-phosphorylated.
Grb7
SHPTP2
1
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate $T1$$T2$ differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bcl-2
Bcl-X-S
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and $T1$-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-$T2$.
Fas
FD8
0
Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including $T1$$T2$ family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.
Bcl-X-L
Bcl-2
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, $T1$, fibronectin, cd44, fibromodulin, and $T2$) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
hyaluronidase
decorin
0
Only the activated and not the latent forms of wild-type and C-terminal mutant des-(248-450)-$T1$ proteins are able to form complexes with $T2$.
MMP-1
TIMP
1
Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like $T1$$T2$ and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.
gammac
IL-13Ralpha
0
Interaction of $T1$ and N+C-SH2 with $T2$ (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
p85
IR beta
1
These findings strongly suggest that CD26 may be closely associated with the CD45 protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of $T1$ with $T2$ results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.
CD26
CD45
1
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed $T1$$T2$ (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
MyoD
MyoD
0
Whereas IL-13Ralpha serves as an alternative accessory protein to the common $T1$ ($T2$) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.
cytokine receptor gamma chain
gammac
0
This activation with p85 and $T1$ was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for $T2$ beta (delta C-43).
IGF-1R beta
IGF-1R
0
Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or $T1$$T2$) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
IGF-1R
delta C-43
0
In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector $T1$$T2$ complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.
p21
E2F
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of $T1$$T2$ (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
cyclinA
MyoD
0
Measurement of RII alpha I3A,I5A interaction with the human $T1$, $T2$, by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold.
thyroid AKAP
Ht 31
0
Bcl-2 also interacted with Bcl-X-L and Mcl-1 and with the dominant inhibitors Bax and Bcl-X-S. $T1$ displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as $T2$.
Bcl-X-L
Bcl-2
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD ($T1$-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of $T2$/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
ER
cyclinA
0
These findings strongly suggest that $T1$ may be closely associated with the $T2$ protein tyrosine phosphatase on T cell surface and further support the notion that the interaction of CD26 with CD45 results in enhanced tyrosine kinase activity, zeta chain phosphorylation, and T cell activation.
CD26
CD45
0
MyoD prevents cyclinA/cdk2 containing $T1$$T2$ prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.
E2F
MyoD
0
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and $T1$$T2$ beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IGF-1R beta
IGF-1R
0
Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta($T1$$T2$ beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
delta C-43
IGF-1R
0
Interactions of the Bcl-2 protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and $T1$$T2$, Mcl-1, and Bax, were explored with a yeast two-hybrid system.
Bax
Bcl-X-S
0
Use of deletion mutants of Bcl-2 suggested that Bcl-2 homodimerization involves interactions between two distinct regions within the Bcl-2 protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing $T1$$T2$ protein, since a LexA protein containing Bcl-2 amino acids 83-218 mediated functional interactions with a B42 fusion protein containing Bcl-2 amino acids 1-81 but did not complement a B42 fusion protein containing Bcl-2 amino acids 83-218.
Bcl-2
Bcl-2
0
Whereas $T1$ serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced $T2$ binding activity.
IL-13Ralpha
IL-2
0
This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta ($T1$$T2$ beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).
delta C-4
IGF-1R
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, $T1$$T2$ in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
FADD
Fas
0
Our data indicate that, in differentiating myocytes, one mechanism through which MyoD induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation-associated cdks-containing $T1$$T2$ upregulation and suppression of the proliferation-associated cdks-containing E2F complexes formation.
E2F
p21
0
Interaction of the p85 subunit of PI 3-kinase with the $T1$ receptor (IR) and the $T2$ (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
insulin
IGF-1 receptor
0
In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector $T1$$T2$ DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.
p21
MyoD
0
This cytotoxicity could be abrogated by B42 fusion proteins containing Bcl-2, Bcl-X-L, or $T1$$T2$, Bcl-X-L, or Mcl-1 but not those containing Bcl-X-S (an alternatively spliced form of Bcl-X that lacks a well-conserved 63-amino acid region).
Mcl-1
Bcl-2
0
In differentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor $T1$$T2$ complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream effector p21 are induced.
MyoD
E2F
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, $T1$, fibronectin, cd44, $T2$, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
hyaluronidase
fibromodulin
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-$T1$$T2$ in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
FD5
Fas
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds $T1$ and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-$T2$ and Fas-FD8.
Fas
LPR
0
Interactions of the Bcl-2 protein with itself and other members of the $T1$$T2$ protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, Mcl-1, and Bax, were explored with a yeast two-hybrid system.
Bcl-2
Bcl-2
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of $T1$$T2$ in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
Fas
Fas
0
Here we report the crystal structure of the $T1$ ectodomain in a dimeric form that is induced by simultaneous binding to $T2$ and a heparin decasaccharide.
FGFR2
FGF1
1
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/$T1$$T2$ activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
cdk2
MyoD
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-$T1$, a mutant of $T2$ possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
FD5
Fas
0
The experiments were performed with the cytoplasmic beta domain (wild type or mutated) of $T1$ and $T2$ and p85 or its subdomains (N + C-SH2, N-SH2, C-SH2, SH3 + N-SH2).
IR
IGF-1R
0
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with $T1$$T2$, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IR
p85
0
An E2F complex containing mainly $T1$ and pRb2/p130 ($T2$-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
E2F4
E2F
0
Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the $T1$ ($T2$) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.
IGF-1 receptor
IGF-1R
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and $T1$$T2$ and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
Fas
Fas
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, $T1$$T2$, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
cd44
hyaluronidase
0
Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by $T1$, a specific inhibitor of the $T2$.
CrmA
interleukin-1 beta-converting enzyme
1
Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta($T1$$T2$(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.
delta C-43
IGF-1R beta
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and $T1$-FD5, a mutant of $T2$ possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.
Fas
Fas
0
The TAFII55-interacting region of $T1$ was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila $T2$.
Sp1
TAFII110
1
$T1$, a novel death domain-containing protein, interacts with the death domain of $T2$ and initiates apoptosis.
FADD
Fas
1
The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant CBP and p300 (a $T1$$T2$ (a CBP-related protein).
CBP
p300
0
Bcl-2 also interacted with Bcl-X-L and $T1$ and with the dominant inhibitors Bax and Bcl-X-S. $T2$ displayed the same pattern of combinatorial interactions with Bcl-2 family proteins as Bcl-2.
Mcl-1
Bcl-X-L
0
Interactions of the $T1$ protein with itself and other members of the Bcl-2 family, including Bcl-X-L, Bcl-X-S, $T2$, and Bax, were explored with a yeast two-hybrid system.
Bcl-2
Mcl-1
1
$T1$ is a lymphoid-specific $T2$ transcription factor that regulates inducible gene expression during T cell activation.
Elf-1
Ets
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of $T1$/$T2$ to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
cyclinA
cdk2
1
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, $T1$$T2$, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
fibronectin
elastin
0
The crystal structure of the $T1$ core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of $T2$ in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.
p53
p53
0
After T cell activation, the phosphorylation of Rb results in the release of $T1$, which is correlated temporally with the activation of $T2$-mediated transcription.
Elf-1
Elf-1
0
Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the $T1$$T2$-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.
interleukin-1 beta-converting enzyme
Fas
0
The findings suggest a model whereby Bax and Bcl-X-S differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/$T1$$T2$ differentially regulate Bcl-2 function, and indicate that requirements for Bcl-2/Bax heterodimerization may be different from those for Bcl-2/Bcl-2 homodimerization.
Bax
Bcl-X-S
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, $T1$$T2$, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
hyaluronic acid synthase 2
procollagen I
0
The carboxy-terminal region of dystrophin has previously been shown to interact directly with alpha1 syntrophin, a cytoplasmic component of the $T1$$T2$, a cytoplasmic component of the dystrophin-glycoprotein complex, by in vitro biochemical studies such as overlay assay or immunoprecipitation.
dystrophin
alpha1 syntrophin
0
This activation with $T1$ and $T2$ was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).
p85
IGF-1R beta
1
TAFII55 is shown to interact with the largest subunit (TAFII230) of human TFIID through its central region and with multiple activators--including $T1$, YY1, USF, CTF, adenoviral $T2$, and human immunodeficiency virus-type 1 Tat proteins--through a distinct amino-terminal domain.
Sp1
E1A
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of $T1$$T2$ activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
E2F
MyoD
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of $T1$$T2$/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
E2F
cyclinA
0
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with $T1$$T2$ beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IR
IR
0
Activation of $T1$ decreases phosphorylation of $T2$ at sites that negatively regulate its DNA-binding activity.
protein kinase C
c-Jun
1
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, $T1$, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and $T2$-FD8.
FADD
Fas
0
Coassociation of CD26 ($T1$) with $T2$ on the surface of human T lymphocytes.
dipeptidyl peptidase IV
CD45
1
Coassociation of $T1$ ($T2$) with CD45 on the surface of human T lymphocytes.
CD26
dipeptidyl peptidase IV
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-$T1$, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-$T2$ and Fas-FD8.
FD5
LPR
0
Our data indicate that, in differentiating myocytes, one mechanism through which MyoD induces permanent cell cycle arrest involves $T1$$T2$ induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation-associated cdks-containing E2F complexes formation.
p21
MyoD
0
The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with $T1$$T2$ and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.
IR
IR beta
0
Bcl-2 also interacted with Bcl-X-L and $T1$ and with the dominant inhibitors Bax and Bcl-X-S. Bcl-X-L displayed the same pattern of combinatorial interactions with $T2$ family proteins as Bcl-2.
Mcl-1
Bcl-2
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein MyoD and the pocket proteins pRb, $T1$ and $T2$/p130.
p107
pRb2
0
The carboxy-terminal region of dystrophin has previously been shown to interact directly with alpha1 syntrophin, a cytoplasmic component of the $T1$$T2$ has previously been shown to interact directly with alpha1 syntrophin, a cytoplasmic component of the dystrophin-glycoprotein complex, by in vitro biochemical studies such as overlay assay or immunoprecipitation.
dystrophin
dystrophin
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD ($T1$$T2$-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
ER
Estrogen Receptor
0
Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like $T1$$T2$ in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.
Fas
FADD
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-$T1$, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and $T2$-FD8.
FD5
Fas
0
Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, $T1$$T2$, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.
fibronectin
collagenase
0
Withdrawal from the cell cycle of differentiating myocytes is regulated by the myogenic basic helix-loop-helix (bHLH) protein $T1$$T2$ (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130.
MyoD
myogenic basic helix-loop-helix
0
Using a subclone of C3H10T1/2 mouse fibroblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/$T1$$T2$-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle.
cdk2
Estrogen Receptor
0
An E2F complex containing mainly E2F4 and $T1$/p130 ($T2$-G0/G1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G1/S complex).
pRb2
E2F
0
Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds $T1$ and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and $T2$-FD8.
Fas
Fas
0
